Snippets from BIO 22: Fujifilm Diosynth’s Martin Meeson

The BioProcess Insider Expression Platform

Jul 8 2022 • 15 mins


In the first of my series of interviews from BIO 2022 in San Diego, I speak with Martin Meeson, CEO of Fujifilm Diosynth Biotechnologies, one of the most prominent contract development and manufacturing organizations (CDMOs).

He talks about the CDMO's part in battling COVID-19, the major capital expenditure projects underway at facilities in Denmark, North Carolina, and elsewhere, and Fujifilm's presence in the advanced therapies space, and why it has chosen to invest in mRNA, gene therapies, and allogeneic -- but not autologous -- cell therapy capabilities.